ABCL-1390: Addition of Fixed Low-Dose Nivolumab to R-DAEPOCH Is Associated With Improved Event-Free Survival in Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Year: 2026
Type: article
Study design: Observational Study
Authors: Runiza Abdurashidova, Yana Mangasarova, Elena Baryakh, Natalia Mikhaylova, Hunan Julhakyan, Tanzila Ushaeva, Aminat Magomedova, Anna Kravtsova, Raisa Dorzhieva, Daria Belkina, Ekaterina Fastova, Ekaterina Gitelzon, Oleg Margolin, Madina Bagova, Inna Krasilnikova, Evgeny Zvonkov, Elena Parovichnikova
Institution: National Medical Research Center for Hematology
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: B-cell lymphoma, nivolumab, DA-EPOCH-R, first-line therapy, immune checkpoint inhibitors, event-free survival, newly diagnosed lymphoma, treatment toxicity, Deauville score, PET/CT response assessment, relapse-free survival, non-relapse mortality, immune-related adverse events, relapsed/refractory lymphoma
Open Access status: closed
OpenAlex ID: W7204706113
